Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. Among authors: lublin f. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: reporting extended results from phase III clinical trials. National Multiple Sclerosis Society Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.
Goodkin DE, Reingold S, Sibley W, Wolinsky J, McFarland H, Cookfair D, Lublin F. Goodkin DE, et al. Among authors: lublin f. Ann Neurol. 1999 Jul;46(1):132-4. doi: 10.1002/1531-8249(199907)46:1<132::aid-ana22>3.0.co;2-z. Ann Neurol. 1999. PMID: 10401793 No abstract available.
Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators.
Wolinsky JS, Narayana PA, Noseworthy JH, Lublin FD, Whitaker JN, Linde A, Gjörstrup P, Sullivan HC. Wolinsky JS, et al. Among authors: lublin fd. Neurology. 2000 May 9;54(9):1734-41. doi: 10.1212/wnl.54.9.1734. Neurology. 2000. PMID: 10802777 Clinical Trial.
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. McDonald WI, et al. Among authors: lublin fd. Ann Neurol. 2001 Jul;50(1):121-7. doi: 10.1002/ana.1032. Ann Neurol. 2001. PMID: 11456302
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Polman CH, et al. Among authors: lublin fd. Ann Neurol. 2005 Dec;58(6):840-6. doi: 10.1002/ana.20703. Ann Neurol. 2005. PMID: 16283615 Review.
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. Polman CH, et al. Among authors: lublin fd. N Engl J Med. 2006 Mar 2;354(9):899-910. doi: 10.1056/NEJMoa044397. N Engl J Med. 2006. PMID: 16510744 Free article. Clinical Trial.
300 results